

New target for Myc-driven cancers

The Problem

- Upregulation of Myc expression is a key driver of many cancers including a range of B-cell lymphomas.
- The transcription factor Mnt is a key regulator of Myc and represents a novel therapeutic avenue for treating Myc dependent lymphomas and solid tumors.
- Mnt acts by downregulating apoptotic machinery, promoting survival of Myc over-expressing lymphoma cells.

The Solution

We are developing novel small molecules that disrupt transcription factor complexes involving Mnt.


A first-in-class Mnt inhibitor has the potential to:

- Target a critical vulnerability in MYC driven lymphomas and leukemias
- Improve clinical outcomes for patients with these diseases
- Synergise with existing therapies

Our Program

- **Progress:** Established a robust screening assay and completed screening over 200,000 compounds, generated biophysical and structural biology assays to inform structure activity relationships and developed in vivo safety and efficacy models.
- **Next steps:** Putative hits are undergoing counter screening and 10pt titration. Undertake genetic in vivo safety and efficacy model experiments

Seeking **partnerships and investment** to progress our small molecule program



Janz. S. Blood (2020) 135: 977–978.

Our Team

Prof. Peter Czabotar, Structural biology
Prof. Suzanne Cory, Mnt biology, Lymphoma

David Segal, PhD, Business Development
segal@wehi.edu.au